CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:GRP78-CAR T cell effector function against solid and brain tumors is controlled by GRP78 expression on T cells.
GRP78-CAR T cell effector function against solid and brain tumors is controlled by GRP78 expression on T cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
缺乏可靶向抗原是开发有效T细胞免疫疗法的一项关键限制。未折叠蛋白反应(UPR)相关成员是理想的免疫治疗靶点,因为UPR调节癌细胞抵抗细胞死亡、维持增殖及发生转移的能力。葡萄糖调节蛋白78(GRP78)是UPR的关键调节因子;多种癌症在内质网(ER)应激升高时会过表达GRP78,并使其转位至细胞表面。我们发现,多种实体瘤和脑肿瘤的细胞表面均高表达GRP78,使其成为有前景的嵌合抗原受体(CAR)T细胞靶点。研究显示,GRP78-CAR-T 细胞在体内外均能识别并杀伤GRP78阳性的脑肿瘤和实体瘤。此外,我们发现T细胞活化时CAR-T 细胞上的GRP78表达会上调,但这一表达具有肿瘤细胞系特异性,并导致GRP78-CAR-T 细胞治疗应答存在异质性。
Lack of targetable antigens is a key limitation for developing successful T cell-based immunotherapies. Members of the unfolded protein response (UPR) represent ideal immunotherapy targets because the UPR regulates the ability of cancer cells to resist cell death, sustain proliferation, and metastasize. Glucose-regulated protein 78 (GRP78) is a key UPR regulator that is overexpressed and translocated to the cell surface of a wide variety of cancers in response to elevated endoplasmic reticulum (ER) stress.
We show that GRP78 is highly expressed on the cell surface of multiple solid and brain tumors, making cell surface GRP78 a promising chimeric antigen receptor (CAR) T cell target.
We demonstrate that GRP78-CAR T cells can recognize and kill GRP78+ brain and solid tumors in vitro and in vivo.
Additionally, our findings demonstrate that GRP78 is upregulated on CAR T cells upon T cell activation; however, this expression is tumor-cell-line specific and results in heterogeneous GRP78-CAR T cell therapeutic response.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。